 |
PDBsum entry 2shp
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Tyrosine phosphatase
|
PDB id
|
|
|
|
2shp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.3.48
- protein-tyrosine-phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate
|
 |
 |
 |
 |
 |
O-phospho-L-tyrosyl-[protein]
|
+
|
H2O
|
=
|
L-tyrosyl-[protein]
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Cell
92:441-450
(1998)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the tyrosine phosphatase SHP-2.
|
|
P.Hof,
S.Pluskey,
S.Dhe-Paganon,
M.J.Eck,
S.E.Shoelson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The structure of the SHP-2 tyrosine phosphatase, determined at 2.0 angstroms
resolution, shows how its catalytic activity is regulated by its two SH2
domains. In the absence of a tyrosine-phosphorylated binding partner, the
N-terminal SH2 domain binds the phosphatase domain and directly blocks its
active site. This interaction alters the structure of the N-SH2 domain,
disrupting its phosphopeptide-binding cleft. Conversely, interaction of the
N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface.
Thus, the N-SH2 domain is a conformational switch; it either binds and inhibits
the phosphatase, or it binds phosphoproteins and activates the enzyme.
Recognition of bisphosphorylated ligands by the tandem SH2 domains is an
integral element of this switch; the C-terminal SH2 domain contributes binding
energy and specificity, but it does not have a direct role in activation.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. The Structure of SHP-2 in Its Autoinhibited,
Closed ConfigurationStructures in (A) and (B) are in similar
orientations. The N- and C-terminal SH2 domains are yellow and
green, respectively; the catalytic PTP domain is blue, and
interdomain linkers (residues 104–111 and 217–220) are white
in both panels.(A) Richardson diagram showing secondary
structure and organization of the domains. Orange, the side
chain of Cys459 (the catalytic nucleophile); dashed lines,
disordered loops.(B) All nonhydrogen atoms of SHP-2 are
displayed. Although SH2 domain–bound peptides are not present
in our structure, residues of both domains known to contact
phosphopeptides ([32]; [15]) are colored red. Note that peptide
binding sites of both SH2 domains are exposed on the molecule
surface. A distinct surface of the N-SH2 domain occupies the
active site of the PTP domain. Magenta, residues of the PTP
signature motif, HCSAGIGRS; these residues participate in
catalysis and phosphate binding.
|
 |
Figure 6.
Figure 6. A Conformational Change in the N-SH2 Domain
Regulates SHP-2(A) An α-carbon trace of the
phosphopeptide-bound A conformation of the N-SH2 domain (red)
([15]) is superimposed on the I state domain in the present
structure (yellow). The domains were superimposed using the
invariant portions of the structure (residues 6–55) as
determined by analysis of difference distance matrix plots with
the program DDMP ( [44]). The molecular surface of the PTP and
C-SH2 domains is shown in blue. Note that in the
peptide-bound A state, the N-SH2 backbone (red) would collide
with the surface of the PTP domain.(B) Molecular surfaces of the
N-SH2 domain from the SHP-2 structure (I state) and the isolated
SH2 domain bound to a phosphopeptide (A state) ([32]); the
domains are oriented similarly according to elements of
secondary structure. Residues of the EF (66–68) and BG
(89–92) loops are green and red, respectively. A stick figure
with carbon colored white, the PDGFR 1009 peptide; blue,
nitrogen; red, oxygen; yellow, phosphorus. Closure of the EF and
BG loops in the I state precludes high-affinity phosphopeptide
binding. The change in shape of the N-SH2 domain that
accompanies phosphopeptide binding destroys surface
complementarity for the PTP active site. Phosphopeptide binding
thus promotes dissociation of the N-SH2 and PTP domains to
generate the active A state of SHP-2.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Cell
(1998,
92,
441-450)
copyright 1998.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
E.Darian,
O.Guvench,
B.Yu,
C.K.Qu,
and
A.D.MacKerell
(2011).
Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
|
| |
Proteins,
79,
1573-1588.
|
 |
|
|
|
|
 |
T.M.Marin,
K.Keith,
B.Davies,
D.A.Conner,
P.Guha,
D.Kalaitzidis,
X.Wu,
J.Lauriol,
B.Wang,
M.Bauer,
R.Bronson,
K.G.Franchini,
B.G.Neel,
and
M.I.Kontaridis
(2011).
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
|
| |
J Clin Invest,
121,
1026-1043.
|
 |
|
|
|
|
 |
C.B.McDonald,
K.L.Seldeen,
B.J.Deegan,
V.Bhat,
and
A.Farooq
(2010).
Assembly of the Sos1-Grb2-Gab1 ternary signaling complex is under allosteric control.
|
| |
Arch Biochem Biophys,
494,
216-225.
|
 |
|
|
|
|
 |
J.D.Nardozzi,
K.Lott,
and
G.Cingolani
(2010).
Phosphorylation meets nuclear import: a review.
|
| |
Cell Commun Signal,
8,
32.
|
 |
|
|
|
|
 |
J.E.Park,
N.K.Soung,
Y.Johmura,
Y.H.Kang,
C.Liao,
K.H.Lee,
C.H.Park,
M.C.Nicklaus,
and
K.S.Lee
(2010).
Polo-box domain: a versatile mediator of polo-like kinase function.
|
| |
Cell Mol Life Sci,
67,
1957-1970.
|
 |
|
|
|
|
 |
K.Teichmann,
T.Kühl,
I.Könnig,
K.Wieligmann,
M.Zacharias,
and
D.Imhof
(2010).
Modulation of SHP-1 phosphatase activity by monovalent and bivalent SH2 phosphopeptide ligands.
|
| |
Biopolymers,
93,
102-112.
|
 |
|
|
|
|
 |
M.L.Randi,
A.M.Brunati,
M.Scapin,
M.Frasson,
R.Deana,
E.Magrin,
F.Fabris,
and
A.Donella-Deana
(2010).
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
|
| |
Blood,
115,
667-676.
|
 |
|
|
|
|
 |
M.Lukosz,
S.Jakob,
N.Büchner,
T.C.Zschauer,
J.Altschmied,
and
J.Haendeler
(2010).
Nuclear redox signaling.
|
| |
Antioxid Redox Signal,
12,
713-742.
|
 |
|
|
|
|
 |
M.Tartaglia,
and
B.D.Gelb
(2010).
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.
|
| |
Ann N Y Acad Sci,
1214,
99.
|
 |
|
|
|
|
 |
M.Tartaglia,
G.Zampino,
and
B.D.Gelb
(2010).
Noonan syndrome: clinical aspects and molecular pathogenesis.
|
| |
Mol Syndromol,
1,
2.
|
 |
|
|
|
|
 |
S.Pati,
G.U.Gurudutta,
O.P.Kalra,
and
A.Mukhopadhyay
(2010).
The structural insights of stem cell factor receptor (c-Kit) interaction with tyrosine phosphatase-2 (Shp-2): An in silico analysis.
|
| |
BMC Res Notes,
3,
14.
|
 |
|
|
|
|
 |
Y.Zorina,
R.Iyengar,
and
K.D.Bromberg
(2010).
Cannabinoid 1 receptor and interleukin-6 receptor together induce integration of protein kinase and transcription factor signaling to trigger neurite outgrowth.
|
| |
J Biol Chem,
285,
1358-1370.
|
 |
|
|
|
|
 |
C.Thiel,
M.Wilken,
M.Zenker,
H.Sticht,
R.Fahsold,
G.C.Gusek-Schneider,
and
A.Rauch
(2009).
Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.
|
| |
Am J Med Genet A,
149,
1263-1267.
|
 |
|
|
|
|
 |
D.Wu,
Y.Pang,
Y.Ke,
J.Yu,
Z.He,
L.Tautz,
T.Mustelin,
S.Ding,
Z.Huang,
and
G.S.Feng
(2009).
A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase.
|
| |
PLoS ONE,
4,
e4914.
|
 |
|
|
|
|
 |
G.Chan,
D.Kalaitzidis,
T.Usenko,
J.L.Kutok,
W.Yang,
M.G.Mohi,
and
B.G.Neel
(2009).
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
|
| |
Blood,
113,
4414-4424.
|
 |
|
|
|
|
 |
H.Zheng,
S.Alter,
and
C.K.Qu
(2009).
SHP-2 tyrosine phosphatase in human diseases.
|
| |
Int J Clin Exp Med,
2,
17-25.
|
 |
|
|
|
|
 |
J.C.Spalton,
J.Mori,
A.Y.Pollitt,
C.E.Hughes,
J.A.Eble,
and
S.P.Watson
(2009).
The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
|
| |
J Thromb Haemost,
7,
1192-1199.
|
 |
|
|
|
|
 |
J.Dengjel,
I.Kratchmarova,
and
B.Blagoev
(2009).
Receptor tyrosine kinase signaling: a view from quantitative proteomics.
|
| |
Mol Biosyst,
5,
1112-1121.
|
 |
|
|
|
|
 |
K.Oishi,
H.Zhang,
W.J.Gault,
C.J.Wang,
C.C.Tan,
I.K.Kim,
H.Ying,
T.Rahman,
N.Pica,
M.Tartaglia,
M.Mlodzik,
and
B.D.Gelb
(2009).
Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development.
|
| |
Hum Mol Genet,
18,
193-201.
|
 |
|
|
|
|
 |
T.Matozaki,
Y.Murata,
Y.Saito,
H.Okazawa,
and
H.Ohnishi
(2009).
Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.
|
| |
Cancer Sci,
100,
1786-1793.
|
 |
|
|
|
|
 |
T.Nakamura,
J.Gulick,
M.C.Colbert,
and
J.Robbins
(2009).
Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development.
|
| |
Proc Natl Acad Sci U S A,
106,
11270-11275.
|
 |
|
|
|
|
 |
U.Lorenz
(2009).
SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.
|
| |
Immunol Rev,
228,
342-359.
|
 |
|
|
|
|
 |
W.E.Tidyman,
and
K.A.Rauen
(2009).
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
|
| |
Curr Opin Genet Dev,
19,
230-236.
|
 |
|
|
|
|
 |
Y.Kulathu,
G.Grothe,
and
M.Reth
(2009).
Autoinhibition and adapter function of Syk.
|
| |
Immunol Rev,
232,
286-299.
|
 |
|
|
|
|
 |
Y.Zhan,
G.J.Counelis,
and
D.M.O'Rourke
(2009).
The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
|
| |
Exp Cell Res,
315,
2343-2357.
|
 |
|
|
|
|
 |
D.Miyamoto,
M.Miyamoto,
A.Takahashi,
Y.Yomogita,
H.Higashi,
S.Kondo,
and
M.Hatakeyama
(2008).
Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
|
| |
Oncogene,
27,
3508-3515.
|
 |
|
|
|
|
 |
D.Xu,
and
C.K.Qu
(2008).
Protein tyrosine phosphatases in the JAK/STAT pathway.
|
| |
Front Biosci,
13,
4925-4932.
|
 |
|
|
|
|
 |
G.Chan,
D.Kalaitzidis,
and
B.G.Neel
(2008).
The tyrosine phosphatase Shp2 (PTPN11) in cancer.
|
| |
Cancer Metastasis Rev,
27,
179-192.
|
 |
|
|
|
|
 |
H.R.Lawrence,
R.Pireddu,
L.Chen,
Y.Luo,
S.S.Sung,
A.M.Szymanski,
M.L.Yip,
W.C.Guida,
S.M.Sebti,
J.Wu,
and
N.J.Lawrence
(2008).
Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds.
|
| |
J Med Chem,
51,
4948-4956.
|
 |
|
|
|
|
 |
I.Lappalainen,
J.Thusberg,
B.Shen,
and
M.Vihinen
(2008).
Genome wide analysis of pathogenic SH2 domain mutations.
|
| |
Proteins,
72,
779-792.
|
 |
|
|
|
|
 |
K.D.Swanson,
Y.Tang,
D.F.Ceccarelli,
F.Poy,
J.P.Sliwa,
B.G.Neel,
and
M.J.Eck
(2008).
The Skap-hom dimerization and PH domains comprise a 3'-phosphoinositide-gated molecular switch.
|
| |
Mol Cell,
32,
564-575.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Tabernero,
A.R.Aricescu,
E.Y.Jones,
and
S.E.Szedlacsek
(2008).
Protein tyrosine phosphatases: structure-function relationships.
|
| |
FEBS J,
275,
867-882.
|
 |
|
|
|
|
 |
M.Krenz,
J.Gulick,
H.E.Osinska,
M.C.Colbert,
J.D.Molkentin,
and
J.Robbins
(2008).
Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
|
| |
Proc Natl Acad Sci U S A,
105,
18930-18935.
|
 |
|
|
|
|
 |
S.Eminaga,
and
A.M.Bennett
(2008).
Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation.
|
| |
J Biol Chem,
283,
15328-15338.
|
 |
|
|
|
|
 |
S.Martinelli,
P.Torreri,
M.Tinti,
L.Stella,
G.Bocchinfuso,
E.Flex,
A.Grottesi,
M.Ceccarini,
A.Palleschi,
G.Cesareni,
L.Castagnoli,
T.C.Petrucci,
B.D.Gelb,
and
M.Tartaglia
(2008).
Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
|
| |
Hum Mol Genet,
17,
2018-2029.
|
 |
|
|
|
|
 |
W.Luo,
R.J.Slebos,
S.Hill,
M.Li,
J.Brábek,
R.Amanchy,
R.Chaerkady,
A.Pandey,
A.J.Ham,
and
S.K.Hanks
(2008).
Global impact of oncogenic Src on a phosphotyrosine proteome.
|
| |
J Proteome Res,
7,
3447-3460.
|
 |
|
|
|
|
 |
W.M.Yu,
O.Guvench,
A.D.Mackerell,
and
C.K.Qu
(2008).
Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay.
|
| |
J Med Chem,
51,
7396-7404.
|
 |
|
|
|
|
 |
X.D.Zhou,
and
Y.M.Agazie
(2008).
Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
|
| |
Cell Death Differ,
15,
988-996.
|
 |
|
|
|
|
 |
Y.Aoki,
T.Niihori,
Y.Narumi,
S.Kure,
and
Y.Matsubara
(2008).
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
|
| |
Hum Mutat,
29,
992.
|
 |
|
|
|
|
 |
Y.T.Bryceson,
and
H.G.Ljunggren
(2008).
Arrestin NK cell cytotoxicity.
|
| |
Nat Immunol,
9,
835-836.
|
 |
|
|
|
|
 |
Z.X.Jiang,
and
Z.Y.Zhang
(2008).
Targeting PTPs with small molecule inhibitors in cancer treatment.
|
| |
Cancer Metastasis Rev,
27,
263-272.
|
 |
|
|
|
|
 |
A.A.Camilleri,
R.Willmann,
G.Sadasivam,
S.Lin,
M.A.Rüegg,
M.Gesemann,
and
C.Fuhrer
(2007).
Tyrosine phosphatases such as SHP-2 act in a balance with Src-family kinases in stabilization of postsynaptic clusters of acetylcholine receptors.
|
| |
BMC Neurosci,
8,
46.
|
 |
|
|
|
|
 |
D.Barua,
J.R.Faeder,
and
J.M.Haugh
(2007).
Structure-based kinetic models of modular signaling protein function: focus on Shp2.
|
| |
Biophys J,
92,
2290-2300.
|
 |
|
|
|
|
 |
G.Bocchinfuso,
L.Stella,
S.Martinelli,
E.Flex,
C.Carta,
F.Pantaleoni,
B.Pispisa,
M.Venanzi,
M.Tartaglia,
and
A.Palleschi
(2007).
Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2.
|
| |
Proteins,
66,
963-974.
|
 |
|
|
|
|
 |
H.Hoff,
and
M.C.Brunner-Weinzierl
(2007).
The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual primary T lymphocytes.
|
| |
Eur J Immunol,
37,
1072-1086.
|
 |
|
|
|
|
 |
K.Becker,
H.Hughes,
K.Howard,
M.Armstrong,
D.Roberts,
E.J.Lazda,
J.P.Short,
A.Shaw,
M.A.Patton,
and
M.Tartaglia
(2007).
Early fetal death associated with compound heterozygosity for Noonan syndrome-causative PTPN11 mutations.
|
| |
Am J Med Genet A,
143,
1249-1252.
|
 |
|
|
|
|
 |
L.I.Pao,
K.Badour,
K.A.Siminovitch,
and
B.G.Neel
(2007).
Nonreceptor protein-tyrosine phosphatases in immune cell signaling.
|
| |
Annu Rev Immunol,
25,
473-523.
|
 |
|
|
|
|
 |
M.Rosário,
R.Franke,
C.Bednarski,
and
W.Birchmeier
(2007).
The neurite outgrowth multiadaptor RhoGAP, NOMA-GAP, regulates neurite extension through SHP2 and Cdc42.
|
| |
J Cell Biol,
178,
503-516.
|
 |
|
|
|
|
 |
O.Guvench,
C.K.Qu,
and
A.D.MacKerell
(2007).
Tyr66 acts as a conformational switch in the closed-to-open transition of the SHP-2 N-SH2-domain phosphotyrosine-peptide binding cleft.
|
| |
BMC Struct Biol,
7,
14.
|
 |
|
|
|
|
 |
R.J.Chan,
and
G.S.Feng
(2007).
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
|
| |
Blood,
109,
862-867.
|
 |
|
|
|
|
 |
S.T.Lee,
C.S.Ki,
and
H.J.Lee
(2007).
Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
|
| |
Clin Genet,
72,
150-155.
|
 |
|
|
|
|
 |
X.Tao,
and
L.Tong
(2007).
Crystal structure of the MAP kinase binding domain and the catalytic domain of human MKP5.
|
| |
Protein Sci,
16,
880-886.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Ren,
Z.Chen,
L.Chen,
N.T.Woods,
G.W.Reuther,
J.Q.Cheng,
H.G.Wang,
and
J.Wu
(2007).
Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.
|
| |
J Biol Chem,
282,
36463-36473.
|
 |
|
|
|
|
 |
A.Ostman,
C.Hellberg,
and
F.D.Böhmer
(2006).
Protein-tyrosine phosphatases and cancer.
|
| |
Nat Rev Cancer,
6,
307-320.
|
 |
|
|
|
|
 |
B.A.Liu,
K.Jablonowski,
M.Raina,
M.Arcé,
T.Pawson,
and
P.D.Nash
(2006).
The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling.
|
| |
Mol Cell,
22,
851-868.
|
 |
|
|
|
|
 |
C.P.Kratz,
M.Nathrath,
P.Freisinger,
P.Dressel,
H.P.Assmuss,
C.Klein,
A.Yoshimi,
S.Burdach,
and
C.M.Niemeyer
(2006).
Lethal proliferation of erythroid precursors in a neonate with a germline PTPN11 mutation.
|
| |
Eur J Pediatr,
165,
182-185.
|
 |
|
|
|
|
 |
D.Imhof,
A.S.Wavreille,
A.May,
M.Zacharias,
S.Tridandapani,
and
D.Pei
(2006).
Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains. Critical roles of residues beyond the pY+3 position.
|
| |
J Biol Chem,
281,
20271-20282.
|
 |
|
|
|
|
 |
E.Bergamin,
J.Wu,
and
S.R.Hubbard
(2006).
Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3.
|
| |
Structure,
14,
1285-1292.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
G.S.Feng
(2006).
Shp2 as a therapeutic target for leptin resistance and obesity.
|
| |
Expert Opin Ther Targets,
10,
135-142.
|
 |
|
|
|
|
 |
I.Takahashi,
M.Utsunomiya,
K.Inoue,
T.Takahashi,
J.Nozaki,
Y.Wada,
G.Takada,
and
A.Koizumi
(2006).
A PTPN11 gene mutation (Y63C) causing Noonan syndrome is not associated with short stature in general population.
|
| |
Tohoku J Exp Med,
208,
255-259.
|
 |
|
|
|
|
 |
J.Burks,
and
Y.M.Agazie
(2006).
Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3.
|
| |
Oncogene,
25,
7166-7179.
|
 |
|
|
|
|
 |
K.Hampel,
I.Kaufhold,
M.Zacharias,
F.D.Böhmer,
and
D.Imhof
(2006).
Phosphopeptide ligands of the SHP-1 N-SH2 domain: effects on binding and stimulation of phosphatase activity.
|
| |
ChemMedChem,
1,
869-877.
|
 |
|
|
|
|
 |
M.Hatakeyama
(2006).
Helicobacter pylori CagA -- a bacterial intruder conspiring gastric carcinogenesis.
|
| |
Int J Cancer,
119,
1217-1223.
|
 |
|
|
|
|
 |
M.Tartaglia,
S.Martinelli,
L.Stella,
G.Bocchinfuso,
E.Flex,
V.Cordeddu,
G.Zampino,
I.Burgt,
A.Palleschi,
T.C.Petrucci,
M.Sorcini,
C.Schoch,
R.Foa,
P.D.Emanuel,
and
B.D.Gelb
(2006).
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.
|
| |
Am J Hum Genet,
78,
279-290.
|
 |
|
|
|
|
 |
N.Wang,
Z.Li,
R.Ding,
G.D.Frank,
T.Senbonmatsu,
E.J.Landon,
T.Inagami,
and
Z.J.Zhao
(2006).
Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling.
|
| |
J Biol Chem,
281,
21878-21883.
|
 |
|
|
|
|
 |
P.Uhlén,
P.M.Burch,
C.I.Zito,
M.Estrada,
B.E.Ehrlich,
and
A.M.Bennett
(2006).
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
|
| |
Proc Natl Acad Sci U S A,
103,
2160-2165.
|
 |
|
|
|
|
 |
R.Merritt,
M.J.Hayman,
and
Y.M.Agazie
(2006).
Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant.
|
| |
Biochim Biophys Acta,
1763,
45-56.
|
 |
|
|
|
|
 |
W.M.Yu,
H.Daino,
J.Chen,
K.D.Bunting,
and
C.K.Qu
(2006).
Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.
|
| |
J Biol Chem,
281,
5426-5434.
|
 |
|
|
|
|
 |
Y.Chen,
J.Takita,
M.Hiwatari,
T.Igarashi,
R.Hanada,
A.Kikuchi,
T.Hongo,
T.Taki,
M.Ogasawara,
A.Shimada,
and
Y.Hayashi
(2006).
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
|
| |
Genes Chromosomes Cancer,
45,
583-591.
|
 |
|
|
|
|
 |
Y.Matoba,
T.Kumagai,
A.Yamamoto,
H.Yoshitsu,
and
M.Sugiyama
(2006).
Crystallographic evidence that the dinuclear copper center of tyrosinase is flexible during catalysis.
|
| |
J Biol Chem,
281,
8981-8990.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.G.Weismann,
A.Hager,
H.Kaemmerer,
C.L.Maslen,
C.D.Morris,
D.Schranz,
J.Kreuder,
and
B.D.Gelb
(2005).
PTPN11 mutations play a minor role in isolated congenital heart disease.
|
| |
Am J Med Genet A,
136,
146-151.
|
 |
|
|
|
|
 |
C.Grundner,
H.L.Ng,
and
T.Alber
(2005).
Mycobacterium tuberculosis protein tyrosine phosphatase PtpB structure reveals a diverged fold and a buried active site.
|
| |
Structure,
13,
1625-1634.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.P.Kratz,
C.M.Niemeyer,
R.P.Castleberry,
M.Cetin,
E.Bergsträsser,
P.D.Emanuel,
H.Hasle,
G.Kardos,
C.Klein,
S.Kojima,
J.Stary,
M.Trebo,
M.Zecca,
B.D.Gelb,
M.Tartaglia,
and
M.L.Loh
(2005).
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
|
| |
Blood,
106,
2183-2185.
|
 |
|
|
|
|
 |
D.He,
X.Song,
L.Liu,
D.H.Burk,
and
G.W.Zhou
(2005).
EGF-stimulation activates the nuclear localization signal of SHP-1.
|
| |
J Cell Biochem,
94,
944-953.
|
 |
|
|
|
|
 |
F.Villa,
M.Deak,
G.B.Bloomberg,
D.R.Alessi,
and
D.M.van Aalten
(2005).
Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer: evidence for a second phosphotyrosine substrate recognition pocket.
|
| |
J Biol Chem,
280,
8180-8187.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Keilhack,
F.S.David,
M.McGregor,
L.C.Cantley,
and
B.G.Neel
(2005).
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
|
| |
J Biol Chem,
280,
30984-30993.
|
 |
|
|
|
|
 |
J.Yang,
S.M.Roe,
M.J.Cliff,
M.A.Williams,
J.E.Ladbury,
P.T.Cohen,
and
D.Barford
(2005).
Molecular basis for TPR domain-mediated regulation of protein phosphatase 5.
|
| |
EMBO J,
24,
1.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Hamada,
M.Kato,
T.Shimizu,
K.Ihara,
T.Mizuno,
and
T.Hakoshima
(2005).
Crystal structure of the protein histidine phosphatase SixA in the multistep His-Asp phosphorelay.
|
| |
Genes Cells,
10,
1.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.M.Sturla,
G.Amorino,
M.S.Alexander,
R.B.Mikkelsen,
K.Valerie,
and
R.K.Schmidt-Ullrichr
(2005).
Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2.
|
| |
J Biol Chem,
280,
14597-14604.
|
 |
|
|
|
|
 |
M.Hatakeyama,
and
H.Higashi
(2005).
Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis.
|
| |
Cancer Sci,
96,
835-843.
|
 |
|
|
|
|
 |
M.Jongmans,
E.A.Sistermans,
A.Rikken,
W.M.Nillesen,
R.Tamminga,
M.Patton,
E.M.Maier,
M.Tartaglia,
K.Noordam,
and
I.van der Burgt
(2005).
Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature.
|
| |
Am J Med Genet A,
134,
165-170.
|
 |
|
|
|
|
 |
M.Nishi,
E.D.Werner,
B.C.Oh,
J.D.Frantz,
S.Dhe-Paganon,
L.Hansen,
J.Lee,
and
S.E.Shoelson
(2005).
Kinase activation through dimerization by human SH2-B.
|
| |
Mol Cell Biol,
25,
2607-2621.
|
 |
|
|
|
|
 |
M.Tartaglia,
and
B.D.Gelb
(2005).
Noonan syndrome and related disorders: genetics and pathogenesis.
|
| |
Annu Rev Genomics Hum Genet,
6,
45-68.
|
 |
|
|
|
|
 |
M.Tartaglia,
S.Martinelli,
I.Iavarone,
G.Cazzaniga,
M.Spinelli,
E.Giarin,
V.Petrangeli,
C.Carta,
R.Masetti,
M.Aricò,
F.Locatelli,
G.Basso,
M.Sorcini,
A.Pession,
and
A.Biondi
(2005).
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
|
| |
Br J Haematol,
129,
333-339.
|
 |
|
|
|
|
 |
R.J.Chan,
M.B.Leedy,
V.Munugalavadla,
C.S.Voorhorst,
Y.Li,
M.Yu,
and
R.Kapur
(2005).
Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
|
| |
Blood,
105,
3737-3742.
|
 |
|
|
|
|
 |
S.F.Bairstow,
K.Ling,
and
R.A.Anderson
(2005).
Phosphatidylinositol phosphate kinase type Igamma directly associates with and regulates Shp-1 tyrosine phosphatase.
|
| |
J Biol Chem,
280,
23884-23891.
|
 |
|
|
|
|
 |
S.Radtke,
S.Haan,
A.Jörissen,
H.M.Hermanns,
S.Diefenbach,
T.Smyczek,
H.Schmitz-Vandeleur,
P.C.Heinrich,
I.Behrmann,
and
C.Haan
(2005).
The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression.
|
| |
J Biol Chem,
280,
25760-25768.
|
 |
|
|
|
|
 |
S.Schubbert,
K.Lieuw,
S.L.Rowe,
C.M.Lee,
X.Li,
M.L.Loh,
D.W.Clapp,
and
K.M.Shannon
(2005).
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
|
| |
Blood,
106,
311-317.
|
 |
|
|
|
|
 |
T.Avril,
S.D.Freeman,
H.Attrill,
R.G.Clarke,
and
P.R.Crocker
(2005).
Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.
|
| |
J Biol Chem,
280,
19843-19851.
|
 |
|
|
|
|
 |
T.Mustelin,
T.Vang,
and
N.Bottini
(2005).
Protein tyrosine phosphatases and the immune response.
|
| |
Nat Rev Immunol,
5,
43-57.
|
 |
|
|
|
|
 |
W.H.Lee,
A.Raas-Rotschild,
M.A.Miteva,
G.Bolasco,
A.Rein,
D.Gillis,
D.Vidaud,
M.Vidaud,
B.O.Villoutreix,
and
B.Parfait
(2005).
Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications.
|
| |
Proteins,
58,
7.
|
 |
|
|
|
|
 |
A.Fragale,
M.Tartaglia,
J.Wu,
and
B.D.Gelb
(2004).
Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
|
| |
Hum Mutat,
23,
267-277.
|
 |
|
|
|
|
 |
A.K.Pedersen,
G.H.Peters G,
K.B.Møller,
L.F.Iversen,
and
J.S.Kastrup
(2004).
Water-molecule network and active-site flexibility of apo protein tyrosine phosphatase 1B.
|
| |
Acta Crystallogr D Biol Crystallogr,
60,
1527-1534.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.Frank,
C.Burkhardt,
D.Imhof,
J.Ringel,
O.Zschörnig,
K.Wieligmann,
M.Zacharias,
and
F.D.Böhmer
(2004).
Effective dephosphorylation of Src substrates by SHP-1.
|
| |
J Biol Chem,
279,
11375-11383.
|
 |
|
|
|
|
 |
D.R.Bertola,
A.C.Pereira,
P.S.de Oliveira,
C.A.Kim,
and
J.E.Krieger
(2004).
Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation.
|
| |
Am J Med Genet A,
130,
378-383.
|
 |
|
|
|
|
 |
G.Charier,
J.Couprie,
B.Alpha-Bazin,
V.Meyer,
E.Quéméneur,
R.Guérois,
I.Callebaut,
B.Gilquin,
and
S.Zinn-Justin
(2004).
The Tudor tandem of 53BP1: a new structural motif involved in DNA and RG-rich peptide binding.
|
| |
Structure,
12,
1551-1562.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Hanafusa,
S.Torii,
T.Yasunaga,
K.Matsumoto,
and
E.Nishida
(2004).
Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty.
|
| |
J Biol Chem,
279,
22992-22995.
|
 |
|
|
|
|
 |
M.Hatakeyama
(2004).
Oncogenic mechanisms of the Helicobacter pylori CagA protein.
|
| |
Nat Rev Cancer,
4,
688-694.
|
 |
|
|
|
|
 |
M.L.Jones,
J.D.Craik,
J.M.Gibbins,
and
A.W.Poole
(2004).
Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus.
|
| |
J Biol Chem,
279,
40475-40483.
|
 |
|
|
|
|
 |
M.R.Zocchi,
and
A.Poggi
(2004).
PECAM-1, apoptosis and CD34+ precursors.
|
| |
Leuk Lymphoma,
45,
2205-2213.
|
 |
|
|
|
|
 |
M.Reth,
and
T.Brummer
(2004).
Feedback regulation of lymphocyte signalling.
|
| |
Nat Rev Immunol,
4,
269-277.
|
 |
|
|
|
|
 |
M.Tartaglia,
C.M.Niemeyer,
K.M.Shannon,
and
M.L.Loh
(2004).
SHP-2 and myeloid malignancies.
|
| |
Curr Opin Hematol,
11,
44-50.
|
 |
|
|
|
|
 |
R.Yoshida,
M.Miyata,
T.Nagai,
T.Yamazaki,
and
T.Ogata
(2004).
A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
|
| |
Am J Med Genet A,
128,
63-66.
|
 |
|
|
|
|
 |
R.Yoshida,
T.Nagai,
T.Hasegawa,
E.Kinoshita,
T.Tanaka,
and
T.Ogata
(2004).
Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome.
|
| |
Am J Med Genet A,
130,
432-434.
|
 |
|
|
|
|
 |
T.Araki,
M.G.Mohi,
F.A.Ismat,
R.T.Bronson,
I.R.Williams,
J.L.Kutok,
W.Yang,
L.I.Pao,
D.G.Gilliland,
J.A.Epstein,
and
B.G.Neel
(2004).
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
|
| |
Nat Med,
10,
849-857.
|
 |
|
|
|
|
 |
A.E.Elia,
P.Rellos,
L.F.Haire,
J.W.Chao,
F.J.Ivins,
K.Hoepker,
D.Mohammad,
L.C.Cantley,
S.J.Smerdon,
and
M.B.Yaffe
(2003).
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain.
|
| |
Cell,
115,
83-95.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.Chan,
A.Lanyi,
H.K.Song,
J.Griesbach,
M.Simarro-Grande,
F.Poy,
D.Howie,
J.Sumegi,
C.Terhorst,
and
M.J.Eck
(2003).
SAP couples Fyn to SLAM immune receptors.
|
| |
Nat Cell Biol,
5,
155-160.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.G.Neel,
H.Gu,
and
L.Pao
(2003).
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.
|
| |
Trends Biochem Sci,
28,
284-293.
|
 |
|
|
|
|
 |
G.Ferjoux,
F.Lopez,
J.P.Esteve,
A.Ferrand,
E.Vivier,
F.Vely,
N.Saint-Laurent,
L.Pradayrol,
L.Buscail,
and
C.Susini
(2003).
Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.
|
| |
Mol Biol Cell,
14,
3911-3928.
|
 |
|
|
|
|
 |
J.Yang,
L.Liu,
D.He,
X.Song,
X.Liang,
Z.J.Zhao,
and
G.W.Zhou
(2003).
Crystal structure of human protein-tyrosine phosphatase SHP-1.
|
| |
J Biol Chem,
278,
6516-6520.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Tartaglia,
C.M.Niemeyer,
A.Fragale,
X.Song,
J.Buechner,
A.Jung,
K.Hählen,
H.Hasle,
J.D.Licht,
and
B.D.Gelb
(2003).
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
|
| |
Nat Genet,
34,
148-150.
|
 |
|
|
|
|
 |
N.R.Pritchard,
and
K.G.Smith
(2003).
B cell inhibitory receptors and autoimmunity.
|
| |
Immunology,
108,
263-273.
|
 |
|
|
|
|
 |
R.Zhao,
X.Fu,
L.Teng,
Q.Li,
and
Z.J.Zhao
(2003).
Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains.
|
| |
J Biol Chem,
278,
42893-42898.
|
 |
|
|
|
|
 |
U.Lehmann,
J.Schmitz,
M.Weissenbach,
R.M.Sobota,
M.Hortner,
K.Friederichs,
I.Behrmann,
W.Tsiaris,
A.Sasaki,
J.Schneider-Mergener,
A.Yoshimura,
B.G.Neel,
P.C.Heinrich,
and
F.Schaper
(2003).
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130.
|
| |
J Biol Chem,
278,
661-671.
|
 |
|
|
|
|
 |
W.Feng,
Y.Shi,
M.Li,
and
M.Zhang
(2003).
Tandem PDZ repeats in glutamate receptor-interacting proteins have a novel mode of PDZ domain-mediated target binding.
|
| |
Nat Struct Biol,
10,
972-978.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.M.Agazie,
and
M.J.Hayman
(2003).
Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates.
|
| |
J Biol Chem,
278,
13952-13958.
|
 |
|
|
|
|
 |
Z.Fu,
E.Aronoff-Spencer,
J.M.Backer,
and
G.J.Gerfen
(2003).
The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling.
|
| |
Proc Natl Acad Sci U S A,
100,
3275-3280.
|
 |
|
|
|
|
 |
A.Veillette,
S.Latour,
and
D.Davidson
(2002).
Negative regulation of immunoreceptor signaling.
|
| |
Annu Rev Immunol,
20,
669-707.
|
 |
|
|
|
|
 |
C.Cebo,
V.Durier,
P.Lagant,
E.Maes,
D.Florea,
T.Lefebvre,
G.Strecker,
G.Vergoten,
and
J.P.Zanetta
(2002).
Function and molecular modeling of the interaction between human interleukin 6 and its HNK-1 oligosaccharide ligands.
|
| |
J Biol Chem,
277,
12246-12252.
|
 |
|
|
|
|
 |
D.G.Woodside,
A.Obergfell,
A.Talapatra,
D.A.Calderwood,
S.J.Shattil,
and
M.H.Ginsberg
(2002).
The N-terminal SH2 domains of Syk and ZAP-70 mediate phosphotyrosine-independent binding to integrin beta cytoplasmic domains.
|
| |
J Biol Chem,
277,
39401-39408.
|
 |
|
|
|
|
 |
G.S.Anand,
and
A.M.Stock
(2002).
Kinetic basis for the stimulatory effect of phosphorylation on the methylesterase activity of CheB.
|
| |
Biochemistry,
41,
6752-6760.
|
 |
|
|
|
|
 |
H.Higashi,
R.Tsutsumi,
A.Fujita,
S.Yamazaki,
M.Asaka,
T.Azuma,
and
M.Hatakeyama
(2002).
Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites.
|
| |
Proc Natl Acad Sci U S A,
99,
14428-14433.
|
 |
|
|
|
|
 |
H.W.Kessels,
A.C.Ward,
and
T.N.Schumacher
(2002).
Specificity and affinity motifs for Grb2 SH2-ligand interactions.
|
| |
Proc Natl Acad Sci U S A,
99,
8524-8529.
|
 |
|
|
|
|
 |
J.Duchene,
J.P.Schanstra,
C.Pecher,
A.Pizard,
C.Susini,
J.P.Esteve,
J.L.Bascands,
and
J.P.Girolami
(2002).
A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation.
|
| |
J Biol Chem,
277,
40375-40383.
|
 |
|
|
|
|
 |
J.M.Cunnick,
S.Meng,
Y.Ren,
C.Desponts,
H.G.Wang,
J.Y.Djeu,
and
J.Wu
(2002).
Regulation of the mitogen-activated protein kinase signaling pathway by SHP2.
|
| |
J Biol Chem,
277,
9498-9504.
|
 |
|
|
|
|
 |
L.A.Maile,
and
D.R.Clemmons
(2002).
Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2.
|
| |
J Biol Chem,
277,
8955-8960.
|
 |
|
|
|
|
 |
L.F.Iversen,
K.B.Moller,
A.K.Pedersen,
G.H.Peters,
A.S.Petersen,
H.S.Andersen,
S.Branner,
S.B.Mortensen,
and
N.P.Moller
(2002).
Structure determination of T cell protein-tyrosine phosphatase.
|
| |
J Biol Chem,
277,
19982-19990.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.B.Yaffe
(2002).
Phosphotyrosine-binding domains in signal transduction.
|
| |
Nat Rev Mol Cell Biol,
3,
177-186.
|
 |
|
|
|
|
 |
M.B.Yaffe
(2002).
MAGUK SH3 domains--swapped and stranded by their kinases?
|
| |
Structure,
10,
3-5.
|
 |
|
|
|
|
 |
M.I.Kontaridis,
X.Liu,
L.Zhang,
and
A.M.Bennett
(2002).
Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts.
|
| |
Mol Cell Biol,
22,
3875-3891.
|
 |
|
|
|
|
 |
M.J.Cross,
L.Lu,
P.Magnusson,
D.Nyqvist,
K.Holmqvist,
M.Welsh,
and
L.Claesson-Welsh
(2002).
The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.
|
| |
Mol Biol Cell,
13,
2881-2893.
|
 |
|
|
|
|
 |
M.Maheshwari,
J.Belmont,
S.Fernbach,
T.Ho,
L.Molinari,
I.Yakub,
F.Yu,
A.Combes,
J.Towbin,
W.J.Craigen,
and
R.Gibbs
(2002).
PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
|
| |
Hum Mutat,
20,
298-304.
|
 |
|
|
|
|
 |
M.Tartaglia,
K.Kalidas,
A.Shaw,
X.Song,
D.L.Musat,
I.van der Burgt,
H.G.Brunner,
D.R.Bertola,
A.Crosby,
A.Ion,
R.S.Kucherlapati,
S.Jeffery,
M.A.Patton,
and
B.D.Gelb
(2002).
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.
|
| |
Am J Hum Genet,
70,
1555-1563.
|
 |
|
|
|
|
 |
Q.Huang,
N.Lerner-Marmarosh,
W.Che,
S.Ohta,
M.Osawa,
M.Yoshizumi,
M.Glassman,
C.Yan,
B.C.Berk,
and
J.Abe
(2002).
The novel role of the C-terminal region of SHP-2. Involvement of Gab1 and SHP-2 phosphatase activity in Elk-1 activation.
|
| |
J Biol Chem,
277,
29330-29341.
|
 |
|
|
|
|
 |
R.A.Lacalle,
E.Mira,
C.Gomez-Mouton,
S.Jimenez-Baranda,
C.Martinez-A,
and
S.Manes
(2002).
Specific SHP-2 partitioning in raft domains triggers integrin-mediated signaling via Rho activation.
|
| |
J Cell Biol,
157,
277-289.
|
 |
|
|
|
|
 |
R.Zhao,
A.Guerrah,
H.Tang,
and
Z.J.Zhao
(2002).
Cell surface glycoprotein PZR is a major mediator of concanavalin A-induced cell signaling.
|
| |
J Biol Chem,
277,
7882-7888.
|
 |
|
|
|
|
 |
T.C.Meng,
T.Fukada,
and
N.K.Tonks
(2002).
Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo.
|
| |
Mol Cell,
9,
387-399.
|
 |
|
|
|
|
 |
T.H.Nguyen,
J.Liu,
and
P.J.Lombroso
(2002).
Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420.
|
| |
J Biol Chem,
277,
24274-24279.
|
 |
|
|
|
|
 |
T.P.Shanley
(2002).
Phosphatases: counterregulatory role in inflammatory cell signaling.
|
| |
Crit Care Med,
30,
S80-S88.
|
 |
|
|
|
|
 |
T.R.Wu,
Y.K.Hong,
X.D.Wang,
M.Y.Ling,
A.M.Dragoi,
A.S.Chung,
A.G.Campbell,
Z.Y.Han,
G.S.Feng,
and
Y.E.Chin
(2002).
SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei.
|
| |
J Biol Chem,
277,
47572-47580.
|
 |
|
|
|
|
 |
W.A.Lim
(2002).
The modular logic of signaling proteins: building allosteric switches from simple binding domains.
|
| |
Curr Opin Struct Biol,
12,
61-68.
|
 |
|
|
|
|
 |
Y.Qi,
R.Zhao,
H.Cao,
X.Sui,
S.B.Krantz,
and
Z.J.Zhao
(2002).
Purification and characterization of protein tyrosine phosphatase PTP-MEG2.
|
| |
J Cell Biochem,
86,
79-89.
|
 |
|
|
|
|
 |
A.Changela,
C.K.Ho,
A.Martins,
S.Shuman,
and
A.Mondragón
(2001).
Structure and mechanism of the RNA triphosphatase component of mammalian mRNA capping enzyme.
|
| |
EMBO J,
20,
2575-2586.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Farooq,
G.Chaturvedi,
S.Mujtaba,
O.Plotnikova,
L.Zeng,
C.Dhalluin,
R.Ashton,
and
M.M.Zhou
(2001).
Solution structure of ERK2 binding domain of MAPK phosphatase MKP-3: structural insights into MKP-3 activation by ERK2.
|
| |
Mol Cell,
7,
387-399.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.L.Smith,
P.Khandelwal,
K.Keliikuli,
E.R.Zuiderweg,
and
M.A.Saper
(2001).
Structure of the type III secretion and substrate-binding domain of Yersinia YopH phosphatase.
|
| |
Mol Microbiol,
42,
967-979.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.P.Berrie
(2001).
Phosphoinositide 3-kinase inhibition in cancer treatment.
|
| |
Expert Opin Investig Drugs,
10,
1085-1098.
|
 |
|
|
|
|
 |
D.J.Dunican,
and
P.Doherty
(2001).
Designing cell-permeant phosphopeptides to modulate intracellular signaling pathways.
|
| |
Biopolymers,
60,
45-60.
|
 |
|
|
|
|
 |
G.Koncz,
G.K.Tóth,
G.Bökönyi,
G.Kéri,
I.Pecht,
D.Medgyesi,
J.Gergely,
and
G.Sármay
(2001).
Co-clustering of Fcgamma and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein.
|
| |
Eur J Biochem,
268,
3898-3906.
|
 |
|
|
|
|
 |
J.N.Andersen,
O.H.Mortensen,
G.H.Peters,
P.G.Drake,
L.F.Iversen,
O.H.Olsen,
P.G.Jansen,
H.S.Andersen,
N.K.Tonks,
and
N.P.Møller
(2001).
Structural and evolutionary relationships among protein tyrosine phosphatase domains.
|
| |
Mol Cell Biol,
21,
7117-7136.
|
 |
|
|
|
|
 |
J.Yang,
T.Niu,
A.Zhang,
A.K.Mishra,
Z.J.Zhao,
and
G.W.Zhou
(2001).
Relation between the flexibility of the WPD loop and the activity of the catalytic domain of protein tyrosine phosphatase SHP-1.
|
| |
J Cell Biochem,
84,
47-55.
|
 |
|
|
|
|
 |
J.Yang,
Z.Cheng,
T.Niu,
X.Liang,
Z.J.Zhao,
and
G.W.Zhou
(2001).
Protein tyrosine phosphatase SHP-1 specifically recognizes C-terminal residues of its substrates via helix alpha0.
|
| |
J Cell Biochem,
83,
14-20.
|
 |
|
|
|
|
 |
L.G.Tertoolen,
C.Blanchetot,
G.Jiang,
J.Overvoorde,
T.W.Gadella,
T.Hunter,
and
J.den Hertog
(2001).
Dimerization of receptor protein-tyrosine phosphatase alpha in living cells.
|
| |
BMC Cell Biol,
2,
8.
|
 |
|
|
|
|
 |
M.Morra,
D.Howie,
M.S.Grande,
J.Sayos,
N.Wang,
C.Wu,
P.Engel,
and
C.Terhorst
(2001).
X-linked lymphoproliferative disease: a progressive immunodeficiency.
|
| |
Annu Rev Immunol,
19,
657-682.
|
 |
|
|
|
|
 |
M.R.Johnson Hamlet,
and
L.A.Perkins
(2001).
Analysis of corkscrew signaling in the Drosophila epidermal growth factor receptor pathway during myogenesis.
|
| |
Genetics,
159,
1073-1087.
|
 |
|
|
|
|
 |
M.Tartaglia,
E.L.Mehler,
R.Goldberg,
G.Zampino,
H.G.Brunner,
H.Kremer,
I.van der Burgt,
A.H.Crosby,
A.Ion,
S.Jeffery,
K.Kalidas,
M.A.Patton,
R.S.Kucherlapati,
and
B.D.Gelb
(2001).
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
|
| |
Nat Genet,
29,
465-468.
|
 |
|
|
|
|
 |
N.K.Tonks,
and
B.G.Neel
(2001).
Combinatorial control of the specificity of protein tyrosine phosphatases.
|
| |
Curr Opin Cell Biol,
13,
182-195.
|
 |
|
|
|
|
 |
C.Blanchetot,
and
J.den Hertog
(2000).
Multiple interactions between receptor protein-tyrosine phosphatase (RPTP) alpha and membrane-distal protein-tyrosine phosphatase domains of various RPTPs.
|
| |
J Biol Chem,
275,
12446-12452.
|
 |
|
|
|
|
 |
C.C.Fjeld,
A.E.Rice,
Y.Kim,
K.R.Gee,
and
J.M.Denu
(2000).
Mechanistic basis for catalytic activation of mitogen-activated protein kinase phosphatase 3 by extracellular signal-regulated kinase.
|
| |
J Biol Chem,
275,
6749-6757.
|
 |
|
|
|
|
 |
C.K.Qu
(2000).
The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions.
|
| |
Cell Res,
10,
279-288.
|
 |
|
|
|
|
 |
D.D.Mousseau,
D.Banville,
D.L'Abbé,
P.Bouchard,
and
S.H.Shen
(2000).
PILRalpha, a novel immunoreceptor tyrosine-based inhibitory motif-bearing protein, recruits SHP-1 upon tyrosine phosphorylation and is paired with the truncated counterpart PILRbeta.
|
| |
J Biol Chem,
275,
4467-4474.
|
 |
|
|
|
|
 |
H.Tang,
Z.J.Zhao,
E.J.Landon,
and
T.Inagami
(2000).
Regulation of calcium-sensitive tyrosine kinase Pyk2 by angiotensin II in endothelial cells. Roles of Yes tyrosine kinase and tyrosine phosphatase SHP-2.
|
| |
J Biol Chem,
275,
8389-8396.
|
 |
|
|
|
|
 |
I.Tamir,
J.M.Dal Porto,
and
J.C.Cambier
(2000).
Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction.
|
| |
Curr Opin Immunol,
12,
307-315.
|
 |
|
|
|
|
 |
J.Yang,
Z.Cheng,
T.Niu,
X.Liang,
Z.J.Zhao,
and
G.W.Zhou
(2000).
Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1.
|
| |
J Biol Chem,
275,
4066-4071.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Zhang,
A.K.Somani,
and
K.A.Siminovitch
(2000).
Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling.
|
| |
Semin Immunol,
12,
361-378.
|
 |
|
|
|
|
 |
L.Li,
and
J.E.Dixon
(2000).
Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases.
|
| |
Semin Immunol,
12,
75-84.
|
 |
|
|
|
|
 |
R.Zhao,
and
Z.J.Zhao
(2000).
Dissecting the interaction of SHP-2 with PZR, an immunoglobulin family protein containing immunoreceptor tyrosine-based inhibitory motifs.
|
| |
J Biol Chem,
275,
5453-5459.
|
 |
|
|
|
|
 |
T.Hunter
(2000).
Signaling--2000 and beyond.
|
| |
Cell,
100,
113-127.
|
 |
|
|
|
|
 |
A.Buist,
Y.L.Zhang,
Y.F.Keng,
L.Wu,
Z.Y.Zhang,
and
J.den Hertog
(1999).
Restoration of potent protein-tyrosine phosphatase activity into the membrane-distal domain of receptor protein-tyrosine phosphatase alpha.
|
| |
Biochemistry,
38,
914-922.
|
 |
|
|
|
|
 |
A.Gjörloff-Wingren,
M.Saxena,
S.Williams,
D.Hammi,
and
T.Mustelin
(1999).
Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP.
|
| |
Eur J Immunol,
29,
3845-3854.
|
 |
|
|
|
|
 |
A.Marie-Cardine,
H.Kirchgessner,
E.Bruyns,
A.Shevchenko,
M.Mann,
F.Autschbach,
S.Ratnofsky,
S.Meuer,
and
B.Schraven
(1999).
SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer regulating human T cell activation.
|
| |
J Exp Med,
189,
1181-1194.
|
 |
|
|
|
|
 |
A.Martin,
H.W.Tsui,
M.J.Shulman,
D.Isenman,
and
F.W.Tsui
(1999).
Murine SHP-1 splice variants with altered Src homology 2 (SH2) domains. Implications for the SH2-mediated intramolecular regulation of SHP-1.
|
| |
J Biol Chem,
274,
21725-21734.
|
 |
|
|
|
|
 |
C.Cantoni,
C.Bottino,
R.Augugliaro,
L.Morelli,
E.Marcenaro,
R.Castriconi,
M.Vitale,
D.Pende,
S.Sivori,
R.Millo,
R.Biassoni,
L.Moretta,
and
A.Moretta
(1999).
Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells.
|
| |
Eur J Immunol,
29,
3148-3159.
|
 |
|
|
|
|
 |
C.Li,
and
J.M.Friedman
(1999).
Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction.
|
| |
Proc Natl Acad Sci U S A,
96,
9677-9682.
|
 |
|
|
|
|
 |
C.Zhou,
D.Horstman,
G.Carpenter,
and
M.F.Roberts
(1999).
Action of phosphatidylinositol-specific phospholipase Cgamma1 on soluble and micellar substrates. Separating effects on catalysis from modulation of the surface.
|
| |
J Biol Chem,
274,
2786-2793.
|
 |
|
|
|
|
 |
G.Koncz,
I.Pecht,
J.Gergely,
and
G.Sármay
(1999).
Fcgamma receptor-mediated inhibition of human B cell activation: the role of SHP-2 phosphatase.
|
| |
Eur J Immunol,
29,
1980-1989.
|
 |
|
|
|
|
 |
H.J.Nam,
F.Poy,
N.X.Krueger,
H.Saito,
and
C.A.Frederick
(1999).
Crystal structure of the tandem phosphatase domains of RPTP LAR.
|
| |
Cell,
97,
449-457.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.Kim,
and
H.Baumann
(1999).
Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
|
| |
Mol Cell Biol,
19,
5326-5338.
|
 |
|
|
|
|
 |
H.Maegawa,
M.Hasegawa,
S.Sugai,
T.Obata,
S.Ugi,
K.Morino,
K.Egawa,
T.Fujita,
T.Sakamoto,
Y.Nishio,
H.Kojima,
M.Haneda,
H.Yasuda,
R.Kikkawa,
and
A.Kashiwagi
(1999).
Expression of a dominant negative SHP-2 in transgenic mice induces insulin resistance.
|
| |
J Biol Chem,
274,
30236-30243.
|
 |
|
|
|
|
 |
J.Blanchette,
N.Racette,
R.Faure,
K.A.Siminovitch,
and
M.Olivier
(1999).
Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-gamma-triggered JAK2 activation.
|
| |
Eur J Immunol,
29,
3737-3744.
|
 |
|
|
|
|
 |
J.Blasioli,
S.Paust,
and
M.L.Thomas
(1999).
Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22.
|
| |
J Biol Chem,
274,
2303-2307.
|
 |
|
|
|
|
 |
J.Brockdorff,
S.Williams,
C.Couture,
and
T.Mustelin
(1999).
Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1.
|
| |
Eur J Immunol,
29,
2539-2550.
|
 |
|
|
|
|
 |
J.L.Evans,
and
B.Jallal
(1999).
Protein tyrosine phosphatases: their role in insulin action and potential as drug targets.
|
| |
Expert Opin Investig Drugs,
8,
139-160.
|
 |
|
|
|
|
 |
K.Nelms,
A.D.Keegan,
J.Zamorano,
J.J.Ryan,
and
W.E.Paul
(1999).
The IL-4 receptor: signaling mechanisms and biologic functions.
|
| |
Annu Rev Immunol,
17,
701-738.
|
 |
|
|
|
|
 |
M.Blery,
and
E.Vivier
(1999).
How to extinguish lymphocyte activation, immunotyrosine-based inhibition motif (ITIM)-bearing molecules a solution?
|
| |
Clin Chem Lab Med,
37,
187-191.
|
 |
|
|
|
|
 |
M.You,
D.H.Yu,
and
G.S.Feng
(1999).
Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway.
|
| |
Mol Cell Biol,
19,
2416-2424.
|
 |
|
|
|
|
 |
P.J.Newman
(1999).
Switched at birth: a new family for PECAM-1.
|
| |
J Clin Invest,
103,
5-9.
|
 |
|
|
|
|
 |
P.Lock,
F.Casagranda,
and
A.R.Dunn
(1999).
Independent SH2-binding sites mediate interaction of Dok-related protein with RasGTPase-activating protein and Nck.
|
| |
J Biol Chem,
274,
22775-22784.
|
 |
|
|
|
|
 |
R.Herbst,
X.Zhang,
J.Qin,
and
M.A.Simon
(1999).
Recruitment of the protein tyrosine phosphatase CSW by DOS is an essential step during signaling by the sevenless receptor tyrosine kinase.
|
| |
EMBO J,
18,
6950-6961.
|
 |
|
|
|
|
 |
T.M.Saxton,
and
T.Pawson
(1999).
Morphogenetic movements at gastrulation require the SH2 tyrosine phosphatase Shp2.
|
| |
Proc Natl Acad Sci U S A,
96,
3790-3795.
|
 |
|
|
|
|
 |
T.Niu,
X.Liang,
J.Yang,
Z.Zhao,
and
G.W.Zhou
(1999).
Kinetic comparison of the catalytic domains of SHP-1 and SHP-2.
|
| |
J Cell Biochem,
72,
145-150.
|
 |
|
|
|
|
 |
T.Ulyanova,
J.Blasioli,
T.A.Woodford-Thomas,
and
M.L.Thomas
(1999).
The sialoadhesin CD33 is a myeloid-specific inhibitory receptor.
|
| |
Eur J Immunol,
29,
3440-3449.
|
 |
|
|
|
|
 |
V.C.Taylor,
C.D.Buckley,
M.Douglas,
A.J.Cody,
D.L.Simmons,
and
S.D.Freeman
(1999).
The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2.
|
| |
J Biol Chem,
274,
11505-11512.
|
 |
|
|
|
|
 |
Y.J.Jin,
C.L.Yu,
and
S.J.Burakoff
(1999).
Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure and catalytic activity.
|
| |
J Biol Chem,
274,
28301-28307.
|
 |
|
|
|
|
 |
Y.P.Lim,
B.C.Low,
J.Lim,
E.S.Wong,
and
G.R.Guy
(1999).
Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling.
|
| |
J Biol Chem,
274,
19025-19034.
|
 |
|
|
|
|
 |
A.Weiss,
and
J.Schlessinger
(1998).
Switching signals on or off by receptor dimerization.
|
| |
Cell,
94,
277-280.
|
 |
|
|
|
|
 |
C.T.Hua,
J.R.Gamble,
M.A.Vadas,
and
D.E.Jackson
(1998).
Recruitment and activation of SHP-1 protein-tyrosine phosphatase by human platelet endothelial cell adhesion molecule-1 (PECAM-1). Identification of immunoreceptor tyrosine-based inhibitory motif-like binding motifs and substrates.
|
| |
J Biol Chem,
273,
28332-28340.
|
 |
|
|
|
|
 |
D.Barford,
and
B.G.Neel
(1998).
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2.
|
| |
Structure,
6,
249-254.
|
 |
|
|
|
|
 |
H.Keilhack,
T.Tenev,
E.Nyakatura,
J.Godovac-Zimmermann,
L.Nielsen,
K.Seedorf,
and
F.D.Böhmer
(1998).
Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling.
|
| |
J Biol Chem,
273,
24839-24846.
|
 |
|
|
|
|
 |
J.Felberg,
and
P.Johnson
(1998).
Characterization of recombinant CD45 cytoplasmic domain proteins. Evidence for intramolecular and intermolecular interactions.
|
| |
J Biol Chem,
273,
17839-17845.
|
 |
|
|
|
|
 |
J.M.Denu,
and
J.E.Dixon
(1998).
Protein tyrosine phosphatases: mechanisms of catalysis and regulation.
|
| |
Curr Opin Chem Biol,
2,
633-641.
|
 |
|
|
|
|
 |
J.Yang,
X.Liang,
T.Niu,
W.Meng,
Z.Zhao,
and
G.W.Zhou
(1998).
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1.
|
| |
J Biol Chem,
273,
28199-28207.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.G.Myers,
R.Mendez,
P.Shi,
J.H.Pierce,
R.Rhoads,
and
M.F.White
(1998).
The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling.
|
| |
J Biol Chem,
273,
26908-26914.
|
 |
|
|
|
|
 |
V.Cleghon,
P.Feldmann,
C.Ghiglione,
T.D.Copeland,
N.Perrimon,
D.A.Hughes,
and
D.K.Morrison
(1998).
Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway.
|
| |
Mol Cell,
2,
719-727.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |